Diagnosed but not treated: How to improve patient access to advanced NSCLC treatment in Europe
Diagnosed but not treated: How to improve patient access to advanced NSCLC treatment in Europe
About this item
Full title
Author / Creator
Publisher
St. Louis: Federal Reserve Bank of St. Louis
Journal title
Language
English
Formats
Publication information
Publisher
St. Louis: Federal Reserve Bank of St. Louis
Subjects
More information
Scope and Contents
Contents
Drug treatment options in advanced non-small cell lung cancer (NSCLC) have multiplied in recent years. 20 new cancer drugs – most of them targeted therapy and immunotherapy – were approved by the European Medicines Agency (EMA) between 2011 and 2020. Measuring if eligible patients have access to drug treatment – both established treatment options a...
Alternative Titles
Full title
Diagnosed but not treated: How to improve patient access to advanced NSCLC treatment in Europe
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2625923562
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2625923562
How to access this item
https://www.proquest.com/docview/2625923562?pq-origsite=primo&accountid=13902
